Mirati Therapeutics | MRTX - Zahlungsmittel Und Äquivalente



Zahlungsmittel Und Äquivalente Veränderung Datum
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amgen USD 9.13B 316M 2025-12
Astellas Pharma JPY 188.37B 8.51B 2025-03
AstraZeneca USD 8.14B 1.08B 2025-09
Bayer EUR 5.9B 1.34B 2025-09
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 7.27B 2.52B 2025-12
Exelixis USD 482.49M 106.19M 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
J&J USD 19.71B 1.48B 2025-12
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Nektar Therapeutics USD 41.03M 1.96M 2025-09
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
Puma Biotechnology USD 53.52M 1.14M 2025-09
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09